Synthesis of oxytocin HYNIC derivatives as potential diagnostic agents for breast cancer

Bioconjugate Chemistry

Volumn 18, Issue 5, 2007, Pages 1560-1567

  Miranda Olvera, Alma D ^a   Ferro Flores, Guillermina ^b   Pedraza López, Martha ^c   De Murphy, Consuelo Arteaga ^c   De León Rodríguez, Luis M ^a,d  

^a UNIVERSITY OF GUANAJUATO   (Mexico)

^b INSTITUTO NACIONAL DE INVESTIGACIONES NUCLEARES   (Mexico)

^c INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^d Instituto de Investigaciones Científicas   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES;

AMINO GROUP; AMINO-ACIDS; BIOCHEMICAL EXPERIMENTS; BREAST CANCER; BREAST CANCER DIAGNOSIS; DIAGNOSTIC AGENTS; FMOC-AMINO ACIDS; LABELING EFFICIENCIES; LABELINGS; SYNTHETIC PROCEDURES;

AMINO ACIDS;

2 HYDRAZINONICOTINIC ACID; N [6 (TERT BUTOXYCARBONYLHYDRAZINEPYRIDINE) 3 CARBOXYL] N ALPHA (FLUORENYLMETHOXYCARBONYL)LYSINE; NICOTINIC ACID DERIVATIVE; OXYTOCIN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BIOCHEMISTRY; BREAST CANCER; CANCER DIAGNOSIS; CONTROLLED STUDY; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; LIGAND BINDING; MALE; MOUSE; NONHUMAN; RECEPTOR AFFINITY;

EID: 34648817023     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc070047a     Document Type: Article

References (21)

1. Griffiths, G. L., Goldenberg, D. M., Jones, A. L., and Hansen, H. J. (1992) Radiolabeling of monoclonal antibodies and fragments with technetium and rhenium. Bioconjugate Chem. 3, 91-99.
2. Smith, G. P. (1985) Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228, 1315-1317.
3. Chilton, H. M., and Witcofski, R. L. (1990) Pharmaceuticals in Medical Imaging. Macmillan Publishing Co., New York.
4. Jurisson, S., Berning, D., Jia, W., and Ma, D. (1993) Coordination Compounds in Nuclear Medicine. Chem. Rev. 93, 1137-1156.
5. 99mTc-Labeled Small Peptides as Diagnostic Radiopharmaceuticals. Chem. Rev. 99, 2235-2268.
6. Abrams, M. J., Juweid, M., tenKate, C. I., Schwartz, D. A., Hauser, M. M., Gaul, F. E., Fuccello, A. J., Rubin, R. H., Strauss, H. W., and Fischman, A. J. (1990) Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J. Nucl. Med. 31, 2022-2028.
7. Decristoforo, C., and Mather, S. J. (1999) 99m-Technetium-labelled peptide-HYNIC conjugates: effects of lipophilicity and stability on biodistribution. Nucl. Med. Biol. 26, 389-396.
8. Dangles, O., Guibe, F., Balavoine, G., Lavielle, S., and Marquet, A. (1987) Selective cleavage of the allyl and (allyloxy)carbonyl groups through palladium-catalyzed hydrostannolysis with tributyltin hydride. Application to the selective protection-deprotection of amino acid derivatives and in peptide synthesis. J. Org. Chem. 52, 4984-4993.
9. Bycroft, B. W., Chan, W. C., Chharbra, S. R., and Hone, N. D. (1993) A novel lysine-protecting procedure for continuous flow solid phase synthesis of branched peptides. J. Chem. Soc.: Chem. Commun. 9, 778-779.
10. Bhorade, R., Weissleder, R., Nakakoshi, T., Moore, A., and Tung, C. H. (2000) Macrocyclic chelators with paramagnetic cations are internalized into mammalian cells via a HIV-Tat derived membrane translocation peptide. Bioconjugate Chem. 11, 301-305.
11. De Leon-Rodriguez, L. M., Kovacs, Z., Dieckmann, G. R., and Sherry, A. D. (2004) Solid-phase synthesis of DOTA-peptides. Chem.-Eur. J. 10, 1149-1155.
12. Greenland, W. E., Howland, K., Hardy, J., Fogelman, I., and Blower, P. J. (2003) Solid-phase synthesis of peptide radiopharmaceuticals using Fmoc-N-epsilon-(hynic-Boc)-lysine, a technetium-binding amino acid: application to Tc-99m-labeled salmon calcitonin. J. Med. Chem. 46, 1751-1757.
13. Gimpl, G., and Fahrenholz, F. (2001) The oxytocin receptor system: structure, function, and regulation. Physiol. Rev. 81, 629-683.
14. Hruby, V. J., Chow, M. S., and Smith, D. D. (1990) Conformational and structural considerations in oxytocin-receptor binding and biological activity. Annu. Rev. Pharmacol. Toxicol. 30, 501-534.
15. Wood, S. P., Tickle, I. J., Treharne, A. M., Pitts, J. E., Mascarenhas, Y., Li, J. Y., Husain, J., Cooper, S., Blundell, T. L., Hruby, V. J., et al. (1986) Crystal structure analysis of deaminooxytocin: conformational flexibility and receptor binding. Science 232, 633-636.
16. Luciani, N., Marie-Claire, C., Ruffet, E., Beaumont, A., Roques, B. P., and Fournie-Zaluski, M. C. (1998) Characterization of Glu350 as a critical residue involved in the N-terminal amine binding site of aminopeptidase N (EC 3.4.11.2): insights into its mechanism of action. Biochemistry 37, 686-692.
17. Zingg, H. H., and Laporte, S. A. (2003) The oxytocin receptor. Trends Endocrinol. Metab. 14, 222-227.
18. Morita, T., Shibata, K., Kikkawa, F., Kajiyama, H., Ino, K., and Mizutani, S. (2004) Oxytocin inhibits the progression of human ovarian carcinoma cells in vitro and in vivo. Int. J. Cancer 109, 525-532.
19. Cassoni, P., Sapino, A., Marrocco, T., Chini, B., and Bussolati, G. (2004) Oxytocin and oxytocin receptors in cancer cells and proliferation. J. Neuroendocrinal. 16, 362-364.
20. Bussolati, G., Chinol, M., Chini, B., Nacca, A., Cassoni, P., and Paganelli, G. (2001) 111In-labeled 1,4,7,10-tetraazacyclododecane-N,N′, N″,N‴-tetraacetic acid-Lys8-vasotocin: a new powerful radioligand for oxytocin receptor-expressing tumors. Cancer Res. 61, 4393-4397.
21. Chini, B., Chinol, M., Cassoni, P., Papi, S., Reversi, A., Areces, L., Marrocco, T., Paganelli, G., Manning, M., and Bussolati, G. (2003) Improved radiotracing of oxytocin receptor-expressing tumors using the new [111In]-DOTA-Lys8-deamino-vasotocin analogue. Br. J. Cancer 89, 930-936.